Lyudmila Bazhenova, MD, Discusses Potential for Trials Featuring Combination IO/Targeted Therapy for EGFR Exon 20+ and Wild Type NSCLC


CancerNetwork® sat down with Lyudmilia Bazhenova, MD, at the 2021 World Conference on Lung Cancer to talk about the feasibility of immunotherapy trials in wild-type and EGFR exon 20 insertion non–small cell lung cancer.

At the 2021 World Conference on Lung Cancer, CancerNetwork® spoke with Lyudmilia Bazhenova, MD, of University of California at San Diego, about why she would not recommend conducting another trial utilizing a single agent immune checkpoint inhibitor in wild-type and EGFR exon 20 insertion non–small cell lung cancer. However, she noted that there may be potential for a trial utilizing immunotherapy plus a lung cancer vaccine.


At this point I’m not aware of any of any trial, and I would be reluctant to do the trial with traditionally approved checkpoint inhibition because I think it’s unlikely that they’re going to work. If we would have a combinatorial immunotherapy trial of maybe a combination of lung cancer vaccines and immunotherapy, I think one can envision doing it. [However], in my practice, I do not use checkpoint inhibition for those patients, and I don’t think I would be comfortable enrolling the patient to a monotherapy immune checkpoint inhibition trial.


Bazhenova L, Girard N, Minchom A, et al. Comparative clinical outcomes between EGFR Exon20ins and wildtype NSCLC treated with immune checkpoint inhibitors. Presented at: 2021 World Conference on Lung Cancer; September 8-14, 2021. Virtual. Accessed September 27, 2021. Abstract P08.04

Related Videos
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Related Content